Extended data Fig. 3: P-G3 treatment improves metabolic health in DIO mice.
From: Selective targeting of visceral adiposity by polycation nanomedicine
a, Western blotting of adipocyte markers and insulin signalling proteins in the eWAT of DIO mice after P-G3 treatment. Representative data were repeated twice independently with similar results. b-e, Mice were treated with P-G3 since the beginning of HFD feeding in Fig. 2. Before sacrifice, mice were fasted overnight and then refed for 4 hours to measure plasma metabolites. Data were represented as mean ± s.e.m. (n = 8, 5). f, g, H&E and PAS staining of glycogen contents (f) and qPCR analysis of gene expression (g) in the liver. Data were represented as mean ± s.e.m. (n = 7, 5). Statistical significance was calculated via 2-tailed Student’s t-test. h, Plasma alanine aminotransferase (ALT) level in another cohort of mice after P-G3 treatment for 6 weeks. Data were represented as mean ± s.e.m. (n = 7, 7). i, j Gene expression of inflammatory and anti-inflammatory markers (i) and F4/80 staining (j) in eWAT from mice with or without P-G3 treatment. Data were represented as mean ± s.e.m. (n = 14, 10). Statistical significance was calculated via 2-tailed Student’s t-test. k-m, Male mice were received 3 dosages of P-G3 (10 mg/kg.BW) or vehicle (intraperitoneally) twice-weekly since the beginning of HFD feeding, then housed singly in metabolic cages for calorimetric analysis. k, Locomotor activity. l, Respiration exchange ratio (RER). m, Food intake within 1 dark/light cycle. Data were represented as mean ± s.e.m. (n = 7, 7). n, Oral fat tolerance test from mice after 6-wk P-G3 treatment. Data were represented as mean ± s.e.m. (n = 7, 7). o, p, Plasma NEFA (o) and glycerol (p) level in mice before and 15 min after the intraperitoneal injection of isoproterenol (10 mg/kg.BW). Data were represented as mean ± s.e.m. (n = 6, 7).
